▶ 調査レポート

癌ペプチドワクチンの世界市場レポート2020

• 英文タイトル:Global Peptide Cancer Vaccine Sales Market Report 2020

QYResearchが調査・発行した産業分析レポートです。癌ペプチドワクチンの世界市場レポート2020 / Global Peptide Cancer Vaccine Sales Market Report 2020 / 20QY06-04962資料のイメージです。• レポートコード:20QY06-04962
• 出版社/出版日:QYResearch / 2020年6月1日
• レポート形態:英文、PDF、148ページ
• 納品方法:Eメール(受注後2~3営業日)
• 産業分類:医薬品・医療
• 販売価格(消費税別)
  Single User¥452,000 (USD4,000)▷ お問い合わせ
  Multi User¥678,000 (USD6,000)▷ お問い合わせ
  Enterprise License¥904,000 (USD8,000)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
QYResearch社の当調査資料では、癌ペプチドワクチンのグローバル市場について種類別(タイプI、タイプII)、用途別(乳癌、肺癌、黒色腫、前立腺癌、その他)、地域別(北米、ヨーロッパ、中国、日本、東南アジア、インド)に区分して調査し、纏めました。2015年~2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。

・癌ペプチドワクチン市場の概要
・世界の主要地域別癌ペプチドワクチン市場規模2015-2026
・主要プレイヤーの競争状況・市場シェア
・世界の癌ペプチドワクチン市場規模2015-2026:種類別(タイプI、タイプII)
・世界の癌ペプチドワクチン市場規模2015-2026:用途別(乳癌、肺癌、黒色腫、前立腺癌、その他)
・癌ペプチドワクチンの北米市場規模2015-2020
・癌ペプチドワクチンのヨーロッパ市場規模2015-2020
・癌ペプチドワクチンの中国市場規模2015-2020
・癌ペプチドワクチンの日本市場規模2015-2020
・癌ペプチドワクチンの東南アジア市場規模2015-2020
・癌ペプチドワクチンのインド市場規模2015-2020
・主要プレイヤーの企業情報:事業概要・売上・企業動向
(TapImmune、BrightPath Biotherapeutics、Ultimovacs、Sellas、Boston Biomedical、Imugene、VAXON Biotech、Generex Biotechnology、ISA Pharmaceuticals、OncoTherapy Science、Immatics)
・癌ペプチドワクチンの製造コスト分析
・販売チャネル、流通業者、顧客
・癌ペプチドワクチンの市場動向・機会・課題
・調査の結論

A recently published report by QY Research titled Global Peptide Cancer Vaccine Sales Market Report 2020 is designed in a way that helps the readers to acquire a complete knowledge about the overall market scenario and it’s most lucrative sectors. The research report also statistically provides accurate data in a statistical manner. It examines the historic accomplishments and recent opportunities present in the global Peptide Cancer Vaccine market. QY Research report focuses on the consumption, geography, by type, by application, and the competitive landscape. The 4000 version of the report mainly splits the data for each region to analyze the leading companies, applications, and product types.
QY Research aims to provide a complete knowledgeable report so that the readers will benefit from it. The report is properly examined and compiled by industry experts and will shed light on the key information that requires from the clients.
Report Overview:
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Peptide Cancer Vaccine market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Peptide Cancer Vaccine industry.
Based on our recent survey, we have several different scenarios about the Peptide Cancer Vaccine YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 418.1 million in 2019. The market size of Peptide Cancer Vaccine will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
QY Research report provides an overview and scope of the global Peptide Cancer Vaccine market, stating its drivers, trends, opportunities, and restraints. The report also comprises all key details of the global Peptide Cancer Vaccine market such as market strategies, sales volumes, and consumption. The report also covers the names of all distribution channels such as manufacturers, suppliers, wholesalers, distributors, consumers, and dealers.
QY Research also presents the statistical data in the form of infographics, tables, and charts to predict the trends and developments of the global Peptide Cancer Vaccine market over the forecast period. The research analysts have also used a framework such as key industry experts interview, research papers, refer journals, survey reports, and face-to-face interviews with expert professionals to know the detailed outlook of the global Peptide Cancer Vaccine market. The report also includes nautical information, where it shows Peptide Cancer Vaccine market product volume, utilization value, and production processes.
The research report also consists of a competitive landscape that describes the top players that are functioning in the global Peptide Cancer Vaccine market. This report also describes the key developments and trends, mergers and acquisitions strategies, and new product innovation that will show an enormous benefit to the companies that are competing in the global Peptide Cancer Vaccine market.
Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
Geographical Analysis:
Based on region, the global Peptide Cancer Vaccine market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Peptide Cancer Vaccine market are
TapImmune
BrightPath Biotherapeutics
Ultimovacs
Sellas
Boston Biomedical
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Immatics
Segment by Type
Type I
Type II
Segment by Application
Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Peptide Cancer Vaccine market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Peptide Cancer Vaccine market.
• The market share of the global Peptide Cancer Vaccine market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Peptide Cancer Vaccine market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Peptide Cancer Vaccine market.

レポート目次

1 Peptide Cancer Vaccine Market Overview
1.1 Peptide Cancer Vaccine Product Scope
1.2 Peptide Cancer Vaccine Segment by Type
1.2.1 Global Peptide Cancer Vaccine Sales by Type (2020-2026)
1.2.2 Type I
1.2.3 Type II
1.3 Peptide Cancer Vaccine Segment by Application
1.3.1 Global Peptide Cancer Vaccine Sales Comparison by Application (2020-2026)
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Melanoma
1.3.5 Prostate Cancer
1.3.6 Others
1.4 Peptide Cancer Vaccine Market Estimates and Forecasts (2015-2026)
1.4.1 Global Peptide Cancer Vaccine Sales Growth Rate (2015-2026)
1.4.2 Global Peptide Cancer Vaccine Revenue and Growth Rate (2015-2026)
1.4.3 Global Peptide Cancer Vaccine Price Trends (2015-2026)
1.5 Coronavirus Disease 2019 (Covid-19): Peptide Cancer Vaccine Industry Impact
1.5.1 How the Covid-19 is Affecting the Peptide Cancer Vaccine Industry
1.5.1.1 Peptide Cancer Vaccine Business Impact Assessment – Covid-19
1.5.1.2 Supply Chain Challenges
1.5.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.5.2 Market Trends and Peptide Cancer Vaccine Potential Opportunities in the COVID-19 Landscape
1.5.3 Measures / Proposal against Covid-19
1.5.3.1 Government Measures to Combat Covid-19 Impact
1.5.3.2 Proposal for Peptide Cancer Vaccine Players to Combat Covid-19 Impact

2 Peptide Cancer Vaccine Estimate and Forecast by Region
2.1 Global Peptide Cancer Vaccine Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Peptide Cancer Vaccine Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Peptide Cancer Vaccine Sales Market Share by Region (2015-2020)
2.2.2 Global Peptide Cancer Vaccine Revenue Market Share by Region (2015-2020)
2.3 Global Peptide Cancer Vaccine Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Peptide Cancer Vaccine Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Peptide Cancer Vaccine Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Peptide Cancer Vaccine Estimates and Projections (2015-2026)
2.4.2 Europe Peptide Cancer Vaccine Estimates and Projections (2015-2026)
2.4.3 China Peptide Cancer Vaccine Estimates and Projections (2015-2026)
2.4.4 Japan Peptide Cancer Vaccine Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Peptide Cancer Vaccine Estimates and Projections (2015-2026)
2.4.6 India Peptide Cancer Vaccine Estimates and Projections (2015-2026)
3 Global Peptide Cancer Vaccine Competition Landscape by Players
3.1 Global Top Peptide Cancer Vaccine Players by Sales (2015-2020)
3.2 Global Top Peptide Cancer Vaccine Players by Revenue (2015-2020)
3.3 Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Cancer Vaccine as of 2019)
3.4 Global Peptide Cancer Vaccine Average Price by Company (2015-2020)
3.5 Manufacturers Peptide Cancer Vaccine Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Peptide Cancer Vaccine Players (Opinion Leaders)
4 Global Peptide Cancer Vaccine Market Size by Type
4.1 Global Peptide Cancer Vaccine Historic Market Review by Type (2015-2020)
4.1.1 Global Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
4.1.2 Global Peptide Cancer Vaccine Revenue Market Share by Type (2015-2020)
4.1.3 Global Peptide Cancer Vaccine Price by Type (2014-2020)
4.2 Global Peptide Cancer Vaccine Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Peptide Cancer Vaccine Sales Forecast by Type (2021-2026)
4.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Type (2021-2026)
4.2.3 Global Peptide Cancer Vaccine Price Forecast by Type (2021-2026)
5 Global Peptide Cancer Vaccine Market Size by Application
5.1 Global Peptide Cancer Vaccine Historic Market Review by Application (2015-2020)
5.1.1 Global Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
5.1.2 Global Peptide Cancer Vaccine Revenue Market Share by Application (2015-2020)
5.1.3 Global Peptide Cancer Vaccine Price by Application (2015-2020)
5.2 Global Peptide Cancer Vaccine Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Peptide Cancer Vaccine Sales Forecast by Application (2021-2026)
5.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Application (2021-2026)
5.2.3 Global Peptide Cancer Vaccine Price Forecast by Application (2021-2026)

3 North America Peptide Cancer Vaccine Market Facts & Figures
3.2 North America Peptide Cancer Vaccine Sales Market Share by Company (2015-2020)
3.3 North America Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
3.4 North America Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)

4 Europe Peptide Cancer Vaccine Market Facts & Figures
4.2 Europe Peptide Cancer Vaccine Sales Market Share by Company (2015-2020)
4.3 Europe Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
4.4 Europe Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)

5 China Peptide Cancer Vaccine Market Facts & Figures
5.2 China Peptide Cancer Vaccine Sales Market Share by Company (2015-2020)
5.3 China Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
5.4 China Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)

6 Japan Peptide Cancer Vaccine Market Facts & Figures
6.2 Japan Peptide Cancer Vaccine Sales Market Share by Company (2015-2020)
6.3 Japan Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
6.4 Japan Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)

7 Southeast Asia Peptide Cancer Vaccine Market Facts & Figures
7.2 Southeast Asia Peptide Cancer Vaccine Sales Market Share by Company (2015-2020)
7.3 Southeast Asia Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
7.4 Southeast Asia Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)

8 India Peptide Cancer Vaccine Market Facts & Figures
8.2 India Peptide Cancer Vaccine Sales Market Share by Company (2015-2020)
8.3 India Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
8.4 India Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)

12 Company Profiles and Key Figures in Peptide Cancer Vaccine Business
12.1 TapImmune
12.1.1 TapImmune Peptide Cancer Vaccine Corporation Information
12.1.2 TapImmune Peptide Cancer Vaccine Business Overview and Total Revenue
12.1.3 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
12.1.4 TapImmune Peptide Cancer Vaccine Products Offered
12.1.5 TapImmune Recent Development
12.2 BrightPath Biotherapeutics
12.2.1 BrightPath Biotherapeutics Peptide Cancer Vaccine Corporation Information
12.2.2 BrightPath Biotherapeutics Peptide Cancer Vaccine Business Overview and Total Revenue
12.2.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
12.2.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Products Offered
12.2.5 BrightPath Biotherapeutics Recent Development
12.3 Ultimovacs
12.3.1 Ultimovacs Peptide Cancer Vaccine Corporation Information
12.3.2 Ultimovacs Peptide Cancer Vaccine Business Overview and Total Revenue
12.3.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Ultimovacs Peptide Cancer Vaccine Products Offered
12.3.5 Ultimovacs Recent Development
12.4 Sellas
12.4.1 Sellas Peptide Cancer Vaccine Corporation Information
12.4.2 Sellas Peptide Cancer Vaccine Business Overview and Total Revenue
12.4.3 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Sellas Peptide Cancer Vaccine Products Offered
12.4.5 Sellas Recent Development
12.5 Boston Biomedical
12.5.1 Boston Biomedical Peptide Cancer Vaccine Corporation Information
12.5.2 Boston Biomedical Peptide Cancer Vaccine Business Overview and Total Revenue
12.5.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Boston Biomedical Peptide Cancer Vaccine Products Offered
12.5.5 Boston Biomedical Recent Development
12.6 Imugene
12.6.1 Imugene Peptide Cancer Vaccine Corporation Information
12.6.2 Imugene Peptide Cancer Vaccine Business Overview and Total Revenue
12.6.3 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
12.6.4 Imugene Peptide Cancer Vaccine Products Offered
12.6.5 Imugene Recent Development
12.7 VAXON Biotech
12.7.1 VAXON Biotech Peptide Cancer Vaccine Corporation Information
12.7.2 VAXON Biotech Peptide Cancer Vaccine Business Overview and Total Revenue
12.7.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
12.7.4 VAXON Biotech Peptide Cancer Vaccine Products Offered
12.7.5 VAXON Biotech Recent Development
12.8 Generex Biotechnology
12.8.1 Generex Biotechnology Peptide Cancer Vaccine Corporation Information
12.8.2 Generex Biotechnology Peptide Cancer Vaccine Business Overview and Total Revenue
12.8.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
12.8.4 Generex Biotechnology Peptide Cancer Vaccine Products Offered
12.8.5 Generex Biotechnology Recent Development
12.9 ISA Pharmaceuticals
12.9.1 ISA Pharmaceuticals Peptide Cancer Vaccine Corporation Information
12.9.2 ISA Pharmaceuticals Peptide Cancer Vaccine Business Overview and Total Revenue
12.9.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
12.9.4 ISA Pharmaceuticals Peptide Cancer Vaccine Products Offered
12.9.5 ISA Pharmaceuticals Recent Development
12.10 OncoTherapy Science
12.10.1 OncoTherapy Science Peptide Cancer Vaccine Corporation Information
12.10.2 OncoTherapy Science Peptide Cancer Vaccine Business Overview and Total Revenue
12.10.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
12.10.4 OncoTherapy Science Peptide Cancer Vaccine Products Offered
12.10.5 OncoTherapy Science Recent Development
12.11 Immatics
12.11.1 Immatics Peptide Cancer Vaccine Corporation Information
12.11.2 Immatics Peptide Cancer Vaccine Business Overview and Total Revenue
12.11.3 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2015-2020)
12.11.4 Immatics Peptide Cancer Vaccine Products Offered
12.11.5 Immatics Recent Development

13 Peptide Cancer Vaccine Manufacturing Cost Analysis
13.1 Peptide Cancer Vaccine Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Peptide Cancer Vaccine
13.4 Peptide Cancer Vaccine Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Peptide Cancer Vaccine Distributors List
14.3 Peptide Cancer Vaccine Customers

15 Market Dynamics
15.1 Market Trends
15.2 Opportunities and Drivers
15.3 Challenges
15.4 Porter’s Five Forces Analysis

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Tables
Table 1. Global Peptide Cancer Vaccine Sales (K Doses) Growth Rate by Type (2020-2026)
Table 2. Global Peptide Cancer Vaccine Sales (K Doses) Comparison by Application (2020-2026)
Table 3. COVID-19 Impact Global Market: (Four Peptide Cancer Vaccine Market Size Forecast Scenarios)
Table 4. Opportunities and Trends for Peptide Cancer Vaccine Players in the COVID-19 Landscape
Table 5. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 6. Key Regions/Countries Measures against Covid-19 Impact
Table 7. Proposal for Peptide Cancer Vaccine Players to Combat Covid-19 Impact
Table 8. Global Market Peptide Cancer Vaccine Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 9. Global Peptide Cancer Vaccine Sales (K Doses) by Region (2015-2020)
Table 10. Global Peptide Cancer Vaccine Sales Market Share by Region (2015-2020)
Table 11. Global Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Region (2015-2020))
Table 12. Global Peptide Cancer Vaccine Revenue Share by Region (2015-2020)
Table 13. Global Peptide Cancer Vaccine Sales (K Doses) Forecast by Region (2021-2026)
Table 14. Global Peptide Cancer Vaccine Sales Market Share Forecast by Region (2021-2026)
Table 15. Global Peptide Cancer Vaccine Revenue (US$ Million) Forecast by Region (2021-2026)
Table 16. Global Peptide Cancer Vaccine Revenue Share Forecast by Region (2021-2026)
Table 17. Global Peptide Cancer Vaccine (K Doses) of Key Companies (2015-2020)
Table 18. Global Peptide Cancer Vaccine Sales Share by Company (2015-2020)
Table 19. Global Peptide Cancer Vaccine Revenue (US$ Million) by Company (2015-2020)
Table 20. Global Peptide Cancer Vaccine Revenue Share by Company (2015-2020)
Table 21. Global Peptide Cancer Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Peptide Cancer Vaccine as of 2019)
Table 22. Global Peptide Cancer Vaccine Average Price (USD/Dose) of Key Company (2015-2020)
Table 23. Manufacturers Peptide Cancer Vaccine Manufacturing Sites and Area Served
Table 24. Manufacturers Peptide Cancer Vaccine Product Type
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Main Points Interviewed from Key Peptide Cancer Vaccine Players
Table 27. Global Peptide Cancer Vaccine Sales (K Doses) by Type (2015-2020)
Table 28. Global Peptide Cancer Vaccine Sales Share by Type (2015-2020)
Table 29. Global Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Type (2015-2020)
Table 30. Global Peptide Cancer Vaccine Price (K Doses) by Type (2015-2020)
Table 31. Global Peptide Cancer Vaccine Sales Share by Type (2021-2026)
Table 32. Global Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Type (2021-2026)
Table 33. Global Peptide Cancer Vaccine Revenue Share by Type (2021-2026)
Table 34. Global Peptide Cancer Vaccine Price (K Doses) by Type (2021-2026)
Table 35. Global Peptide Cancer Vaccine Sales (K Doses) by Application (2015-2020)
Table 36. Global Peptide Cancer Vaccine Sales Share by Application (2015-2020)
Table 37. Global Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Application (2015-2020)
Table 38. Global Peptide Cancer Vaccine Price (K Doses) by Application (2015-2020)
Table 39. Global Peptide Cancer Vaccine Sales (K Doses) by Application (2021-2026)
Table 40. Global Peptide Cancer Vaccine Sales Share by Application (2021-2026)
Table 41. Global Peptide Cancer Vaccine Revenue (US$ Million) Market Share by Application (2021-2026)
Table 42. Global Peptide Cancer Vaccine Revenue Share by Application (2021-2026)
Table 43. Global Peptide Cancer Vaccine Price (K Doses) by Application (2021-2026)
Table 44. United States Peptide Cancer Vaccine Sales (K Doses) by Company (2015-2020)
Table 45. United States Peptide Cancer Vaccine Sales Market Share by Company (2015-2020)
Table 46. United States Peptide Cancer Vaccine Sales (K Doses) by Type (2015-2020)
Table 47. United States Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Table 48. United States Peptide Cancer Vaccine Sales (K Doses) by Application (2015-2020)
Table 49. United States Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Table 50. Europe Peptide Cancer Vaccine Sales (K Doses) by Company (2015-2020)
Table 51. Europe Peptide Cancer Vaccine Sales Market Share by Company (2015-2020)
Table 52. Europe Peptide Cancer Vaccine Sales (K Doses) by Type (2015-2020)
Table 53. Europe Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Table 54. Europe Peptide Cancer Vaccine Sales (K Doses) by Application (2015-2020)
Table 55. Europe Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Table 56. China Peptide Cancer Vaccine Sales (K Doses) by Company (2015-2020)
Table 57. China Peptide Cancer Vaccine Sales Market Share by Company (2015-2020)
Table 58. China Peptide Cancer Vaccine Sales (K Doses) by Type (2015-2020)
Table 59. China Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Table 60. China Peptide Cancer Vaccine Sales (K Doses) by Application (2015-2020)
Table 61. China Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Table 62. Japan Peptide Cancer Vaccine Sales (K Doses) by Company (2015-2020)
Table 63. Japan Peptide Cancer Vaccine Sales Market Share by Company (2015-2020)
Table 64. Japan Peptide Cancer Vaccine Sales (K Doses) by Type (2015-2020)
Table 65. Japan Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Table 66. Japan Peptide Cancer Vaccine Sales (K Doses) by Application (2015-2020)
Table 67. Japan Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Table 68. Southeast Asia Peptide Cancer Vaccine Sales (K Doses) by Company (2015-2020)
Table 69. Southeast Asia Peptide Cancer Vaccine Sales Market Share by Company (2015-2020)
Table 70. Southeast Asia Peptide Cancer Vaccine Sales (K Doses) by Type (2015-2020)
Table 71. Southeast Asia Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Table 72. Southeast Asia Peptide Cancer Vaccine Sales (K Doses) by Type (2015-2020)
Table 73. Southeast Asia Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Table 74. India Peptide Cancer Vaccine Sales (K Doses) by Company (2015-2020)
Table 75. India Peptide Cancer Vaccine Sales Market Share by Company (2015-2020)
Table 76. India Peptide Cancer Vaccine Sales (K Doses) by Type (2015-2020)
Table 77. India Peptide Cancer Vaccine Sales Market Share by Type (2015-2020)
Table 78. India Peptide Cancer Vaccine Sales (K Doses) by Application (2015-2020)
Table 79. India Peptide Cancer Vaccine Sales Market Share by Application (2015-2020)
Table 80. TapImmune Corporation Information
Table 81. TapImmune Description and Business Overview
Table 82. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2015-2020)
Table 83. TapImmune Peptide Cancer Vaccine Product
Table 84. TapImmune Recent Development
Table 85. BrightPath Biotherapeutics Corporation Information
Table 86. BrightPath Biotherapeutics Description and Business Overview
Table 87. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2015-2020)
Table 88. BrightPath Biotherapeutics Peptide Cancer Vaccine Product
Table 89. BrightPath Biotherapeutics Recent Development
Table 90. Ultimovacs Corporation Information
Table 91. Ultimovacs Description and Business Overview
Table 92. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2015-2020)
Table 93. Ultimovacs Peptide Cancer Vaccine Product
Table 94. Ultimovacs Recent Development
Table 95. Sellas Corporation Information
Table 96. Sellas Description and Business Overview
Table 97. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2015-2020)
Table 98. Sellas Peptide Cancer Vaccine Product
Table 99. Sellas Recent Development
Table 100. Boston Biomedical Corporation Information
Table 101. Boston Biomedical Description and Business Overview
Table 102. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2015-2020)
Table 103. Boston Biomedical Peptide Cancer Vaccine Product
Table 104. Boston Biomedical Recent Development
Table 105. Imugene Corporation Information
Table 106. Imugene Description and Business Overview
Table 107. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2015-2020)
Table 108. Imugene Peptide Cancer Vaccine Product
Table 109. Imugene Recent Development
Table 110. VAXON Biotech Corporation Information
Table 111. VAXON Biotech Description and Business Overview
Table 112. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2015-2020)
Table 113. VAXON Biotech Peptide Cancer Vaccine Product
Table 114. VAXON Biotech Recent Development
Table 115. Generex Biotechnology Corporation Information
Table 116. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2015-2020)
Table 117. Generex Biotechnology Description and Business Overview
Table 118. Generex Biotechnology Peptide Cancer Vaccine Product
Table 119. Generex Biotechnology Recent Development
Table 120. ISA Pharmaceuticals Corporation Information
Table 121. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2015-2020)
Table 122. ISA Pharmaceuticals Description and Business Overview
Table 123. ISA Pharmaceuticals Peptide Cancer Vaccine Product
Table 124. ISA Pharmaceuticals Recent Development
Table 125. OncoTherapy Science Corporation Information
Table 126. OncoTherapy Science Description and Business Overview
Table 127. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2015-2020)
Table 128. OncoTherapy Science Peptide Cancer Vaccine Product
Table 129. OncoTherapy Science Recent Development
Table . Immatics Corporation Information
Table . Immatics Description and Business Overview
Table . Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2015-2020)
Table . Immatics Peptide Cancer Vaccine Product
Table . Immatics Recent Development
Table 135. Production Base and Market Concentration Rate of Raw Material
Table 136. Key Suppliers of Raw Materials
Table 137. Peptide Cancer Vaccine Distributors List
Table 138. Peptide Cancer Vaccine Customers List
Table 139. Market Key Trends
Table 140. Key Opportunities and Drivers: Impact Analysis (2020-2026)
Table 141. Key Challenges
Table 142. Research Programs/Design for This Report
Table 143. Key Data Information from Secondary Sources
Table 144. Key Data Information from Primary Sources
List of Figures
Figure 1. Peptide Cancer Vaccine Product Picture
Figure 2. Global Peptide Cancer Vaccine Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Peptide Cancer Vaccine Market Share by Application in 2020 & 2026
Figure 6. Breast Cancer Examples
Figure 7. Lung Cancer Examples
Figure 8. Melanoma Examples
Figure 9. Prostate Cancer Examples
Figure 10. Others Examples
Figure 11. Global Peptide Cancer Vaccine Sales (K Doses) Growth Rate (2015-2026)
Figure 12. Global Peptide Cancer Vaccine Revenue (US$ Million) Growth Rate (2015-2026)
Figure 13. Global Peptide Cancer Vaccine Price Trends Growth Rate (2015-2026) (USD/Dose)
Figure 14. Global Peptide Cancer Vaccine Revenue Market Share by Region: 2015 VS 2020
Figure 15. Global Peptide Cancer Vaccine Revenue Market Share by Region: 2021 VS 2026
Figure 16. United States Peptide Cancer Vaccine Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. United States Peptide Cancer Vaccine Sales (K Doses) Growth Rate (2015-2026)
Figure 18. Europe Peptide Cancer Vaccine Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. Europe Peptide Cancer Vaccine Sales (Million USD) Growth Rate (2015-2026)
Figure 20. China Peptide Cancer Vaccine Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. China Peptide Cancer Vaccine Sales (Million USD) and Growth Rate (2015-2026)
Figure 22. Japan Peptide Cancer Vaccine Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Japan Peptide Cancer Vaccine Sales (Million USD) Growth Rate (2015-2026)
Figure 24. Southeast Asia Peptide Cancer Vaccine Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. Southeast Asia Peptide Cancer Vaccine Sales (Million USD) Growth Rate (2015-2026)
Figure 26. India Peptide Cancer Vaccine Revenue (Million USD) Growth Rate (2015-2026)
Figure 27. India Peptide Cancer Vaccine Sales (Million USD) Growth Rate (2015-2026)
Figure 28. Global 5 Largest Peptide Cancer Vaccine Players Market Share by Revenue in Peptide Cancer Vaccine 2015 & 2019
Figure 29. Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 30. Global Peptide Cancer Vaccine Revenue Share by Type (2015-2020)
Figure 31. Global Peptide Cancer Vaccine Revenue Growth Rate by Type in 2015 & 2019
Figure 32. Global Peptide Cancer Vaccine Revenue Share by Application (2015-2020)
Figure 33. Global Peptide Cancer Vaccine Revenue Growth Rate by Application in 2015 & 2019
Figure 34. United States Peptide Cancer Vaccine Sales Market Share by Type in 2019
Figure 35. United States Peptide Cancer Vaccine Sales Market Share by Type in 2019
Figure 36. Europe Peptide Cancer Vaccine Sales Market Share by Company in 2019
Figure 37. Europe Peptide Cancer Vaccine Sales Market Share by Type in 2019
Figure 38. Europe Peptide Cancer Vaccine Sales Market Share by Application in 2019
Figure 39. China Peptide Cancer Vaccine Sales Market Share by Company in 2019
Figure 40. China Peptide Cancer Vaccine Sales Market Share by Type in 2019
Figure 41. China Peptide Cancer Vaccine Sales Market Share by Application in 2019
Figure 42. Japan Peptide Cancer Vaccine Sales Market Share by Company in 2019
Figure 43. Japan Peptide Cancer Vaccine Sales Market Share by Type in 2019
Figure 44. Japan Peptide Cancer Vaccine Sales Market Share by Application in 2019
Figure 45. Southeast Asia Peptide Cancer Vaccine Sales Market Share by Company in 2019
Figure 46. Southeast Asia Peptide Cancer Vaccine Sales Market Share by Type in 2019
Figure 47. Southeast Asia Peptide Cancer Vaccine Sales Market Share by Application in 2019
Figure 48. India Peptide Cancer Vaccine Sales Market Share by Company in 2019
Figure 49. India Peptide Cancer Vaccine Sales Market Share by Type in 2019
Figure 50. India Peptide Cancer Vaccine Sales Market Share by Application in 2019
Figure 51. TapImmune Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. BrightPath Biotherapeutics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Ultimovacs Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Sellas Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Boston Biomedical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Imugene Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. VAXON Biotech Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Generex Biotechnology Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. ISA Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. OncoTherapy Science Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Immatics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Key Raw Materials Price Trend
Figure 63. Manufacturing Cost Structure of Peptide Cancer Vaccine
Figure 64. Manufacturing Process Analysis of Peptide Cancer Vaccine
Figure 65. Peptide Cancer Vaccine Industrial Chain Analysis
Figure 66. Channels of Distribution
Figure 67. Distributors Profiles
Figure 68. Porter's Five Forces Analysis
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed